A Study of Repotrectinib in Pediatric and Young Adult Subjects Harboring ALK, ROS1, OR NTRK1-3 Alterations
A phase 1/2 trial of Repotrectinib in non-Hodgkin lymphoma and brain and spinal cord tumours, run by Turning Point Therapeutics, Inc., now recruiting.
Overview
A Study of Repotrectinib in Pediatric and Young Adult Subjects Harboring ALK, ROS1, OR NTRK1-3 Alterations is a phase 1/2 interventional study registered as NCT04094610 by Turning Point Therapeutics, Inc., with 75 participants planned, started 2020-03-12 and due to reach its primary completion in 2026-09-30. Interventions recorded: Oral repotrectinib (TPX-0005).
Similar pages
not linked directly; found by shared links- TrialA Study of Repotrectinib (TPX-0005) in Patients With Advanced Solid Tumors Harboring ALK, ROS1, or NTRK1-3 Rearrangements
Shares Repotrectinib and the tag pipeline.
- TrialStudy of ICP-723 in Patients With Advanced Solid Tumors or Primary Central Nervous System Tumors
Shares Brain and spinal cord tumours (all types) and the tag pipeline.
- TrialA Pivotal Phase II Clinical Trial of Utidelone Injection Plus Capecitabine in HER2-negative Breast Cancer Patients With Brain Metastases
Shares Brain and spinal cord tumours (all types) and the tag pipeline.
- TrialPhase II Clinical Trial of CNCT19 Cell Injection in the Treatment of Relapsed or Refractory Non-Hodgkin's Lymphoma
Shares Non-Hodgkin lymphoma (all types) and the tag pipeline.
- TrialClinical Study of U16 in Patients With Relapsed or Refractory Non-Hodgkin's Lymphoma
Shares Non-Hodgkin lymphoma (all types) and the tag pipeline.
- TrialA Study Evaluating the Safety and Efficacy of BEAM-201 in Relapsed/Refractory T-Cell Acute Lymphoblastic Leukemia (T-ALL) or T-Cell Lymphoblastic Lymphoma (T-LL)
Shares Non-Hodgkin lymphoma (all types) and the tag pipeline.
- TrialMB-105 in Patients With CD5 Positive T-cell Lymphoma
Shares Non-Hodgkin lymphoma (all types) and the tag pipeline.
- TrialGT719 Injection for the Treatment of Recurrent/Refractory CD19 Positive Adult B-cell Malignancies
Shares Non-Hodgkin lymphoma (all types) and the tag pipeline.